BioPharmSignal logoBioPharmSignal

Biotech News

Iridex Reports Third Quarter 2025 Financial Results

IRIDEX (IRIX)IRIDEX2026-06-25 13:46 ESTEarnings

MOUNTAIN VIEW, Calif. , Nov. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results

Open original release

Related news

IRIXIRIDEX2026-06-25 13:46 EST

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

IRIXIRIDEX2026-06-25 13:46 EST

Iridex Reports First Quarter 2026 Financial Results

IRIXIRIDEX2026-06-25 13:46 EST

Iridex to Present at the Sidoti Year-End Virtual Investor Conference

IRIXIRIDEX2026-06-25 13:46 EST

Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment

IRIXIRIDEX2026-06-25 13:46 EST

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

IRIXIRIDEX2026-06-25 13:46 EST

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

IRIXIRIDEX2026-06-25 13:46 EST

Iridex Announces Plans to Relocate Headquarters

IRIXIRIDEX2026-06-25 13:46 EST

Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

IRIXIRIDEX2026-06-25 13:46 EST

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

IRIXIRIDEX2026-06-25 13:46 EST

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology

View all latest news

IRIDEX

IRIDEX is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

IRIXZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

IRIXZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

IRIXBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

IRIXGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

IRIXMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close
1.07 USD
Market cap
19.15M USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States